ENDRA Life Sciences
Developing radio-frequency thermoacoustic ultrasound for point-of-care liver-fat measurement.
Something off on this page? Send us feedback.
Profile
Develops the TAEUS Liver system, which pairs radio-frequency thermoacoustics with conventional ultrasound to estimate liver fat for metabolic-disease assessment and clinical-trial screening. Its current business remains pre-revenue and dependent on regulatory authorization, resources, external partners, and a pending merger.
Develops the TAEUS platform, which combines pulsed radio-frequency energy, ultrasound sensors, and proprietary algorithms to assess tissue composition. Its lead TAEUS Liver/FLIP device is designed to work beside conventional ultrasound to estimate liver fat for metabolic-disease assessment, therapy-response monitoring, and clinical-trial screening. Other uses, including temperature monitoring, vascular imaging, and perfusion analysis, remain in development.
Plans subscription arrangements, capital-equipment sales with service and upgrades, and potential licensing to ultrasound or thermoablation equipment makers, subject to regulatory approval and resources. U.S. FDA marketing authorization and EU MDR recertification remain requirements; a pending merger could change the business focus.
Company facts
Key statistics
Year to date +16.7% · Average volume (30d) 15.8K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.84 | −$0.63 | +25.0% | $100.0K | — | — | 0.00% |
| May 18, 2026Q1 FY26 | −$1.23 | −$1.09 | +11.4% | — | — | — | +3.33% |
| Mar 31, 2026Q4 FY25 | −$1.23 | −$3.26 | −165.0% | $100.0K | — | — | 0.00% |
| Nov 14, 2025Q3 FY25 | −$1.95 | −$1.75 | +10.3% | — | — | — | −7.46% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$39.7K | $0 | |
| Operating income | −$1.5M | −$1.3M | −$1.4M | −$1.6M | −$2.2M | −$1.5M | |
| Net income | −$1.0M | −$1.2M | −$1.6M | −$3.2M | −$1.3M | $159.9K | |
| Diluted EPS | −$1.86 | −$1.71 | −$2.10 | −$3.26 | −$1.09 | $0.06 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $1.7M · Total debt $429.3K · Total assets $7.9M · Shareholders' equity $6.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.27M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Anthony DiGiandomenico | 196.7K | 9.90% | 13D | Jun 29, 2026 |
| ATW Master Fund V LP | 116.0K | 9.90% | 13G | Oct 28, 2025 |
| John Carter Lipman | 115.5K | 9.99% | 13G | Oct 30, 2025 |
| Alexander Y. Tokman · director, officer: Chief Executive Officer | 101.9K | 8.03% | Form 4 | Mar 4, 2026 |
| Michael Harsh · director | 65.7K | 5.17% | Form 4 | Jan 23, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- GE HealthCare
Broad imaging alternatives for liver-fat assessment.
- Philips (ADR)
Established imaging alternatives for non-invasive liver assessment.
- Medtronic
Thermal-ablation monitoring alternative in a developmental use case.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ENDRA Life Sciences | $5.11 | +2.10% | $6.4M | — | — | — | — |
| GE HealthCare | $71.73 | −0.01% | $32.40B | 20.8 | 13.8 | 1.6 | +5.8% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Median | 20.8 | 13.8 | 1.6 | +5.8% |